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Abstract
Background: The heat shock proteins (HSPs) 27-kDa (HSP27) and 72-kDa (HSP72), are ubiquitous
chaperone molecules inducible in cells exposed to different stress conditions. Increased level of HSPs are
reported in several human cancers, and found to be associated with the resistance to some anticancer
treatments and poor prognosis. However, there is no study of the relationship between HSPs expression
and patient's prognosis in intrahepatic cholangiocarcinoma (IHCCA). In this exploratory retrospective
study, we investigated the expressions of HSP27 and HSP72 as potential prognostic factors in IHCCA.
Methods: Thirty-one paraffin-embedded samples were analyzed by immunohistochemical methods using
HSP27 and HSP72 monoclonal antibodies. Proliferation rate was assessed in the same specimens by using
monoclonal antibody against phosphorylated histone H3 (pHH3). Fisher's exact test was used to assess
the hypothesis of independence between categorical variables in 2 × 2 tables. The ANOVA procedure was
used to evaluate the association between ordinal and categorical variables. Estimates of the survival
probability were calculated using the Kaplan-Meier method, and the log rank test was employed to test
the null hypothesis of equality in overall survival among groups. The hazard ratio associated with HSP27
and HSP72 expression was estimated by Cox hazard-proportional regression.
Results: The expression of HSP27 was related to mitotic index, tumor greatest dimension, capsular and
vascular invasion while the expression of HSP72 was only related to the presence of necrosis and the
lymphoid infiltration. Kaplan-Maier analysis suggested that the expression of HSP27 significantly worsened
the patients' median overall survival (11 ± 3.18 vs 55 ± 4.1 months, P-value = 0.0003). Moreover HSP27-
positive patients exhibited the worst mean survival (7.0 ± 3.2 months) in the absence of concomitant
HSP72 expression.
Conclusion: The expression of HSP27, likely increasing cell proliferation, tumor mass, vascular and
capsular invasion, might promote aggressive tumor behaviour in IHCCA and decrease patients' survival.
Immunohistochemical detection of HSP27 on routine sections may provide a reliable prognostic marker
for IHCCA able to influence the therapeutic strategies for this cancer.
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Background
Cholangiocarcinoma is a malignant epithelial tumor
derived from the bile duct epithelium and the second
most common primary hepatobiliary cancer, after hepato-
cellular carcinoma[1]. Cholangiocarcinoma remains a rel-
atively rare disease, accounting for <2% of all human
malignancies [2]. Despite aggressive screening, most
patients thought to have localized disease at diagnosis
present with advanced stage tumor not amenable to surgi-
cal treatment. Chemotherapy and radiotherapy are inef-
fective in patients with inoperable tumors, and biliary
drainage is the mainstay of palliation[3]. The median sur-
vival time for patients with intrahepatic cholangiocarci-
noma without hilar involvement varies from 18–30
months.
HSPs are one of the most evolutionarily conserved classes
of molecules and play a fundamental role in the mainte-
nance of cellular homeostasis. Under physiological condi-
tions, they act as molecular chaperones, by assisting
protein folding, oligomerization and translocation[4].
During stress they are overexpressed, preventing aggrega-
tion and promoting refolding of damaged proteins. Apop-
tosis resistance is often associated with high expression of
heat-shock proteins [5-7] (HSPs), and various HSPs
inhibitors can induce apoptosis in many tumor models
[8]. These mechanisms underscore the role of HSPs in
tumor progression and resistance to treatment [9]. The
mechanism of HSPs overexpression in cancer is still a mat-
ter of debate [10]. The physiopathological features of the
tumor microenvironment such as low glucose, low pH
and low oxygen are likely to be involved.
In spite of these observations, attempts to correlate the
levels of HSPs in tumor samples with clinical prognosis
and progression in man have provided controversial
results.
We focused our attention on intrahepatic cholangiocarci-
noma (IHCCA), prompted by epidemiological data,
showing a marked increase incidence in our province as
well as in the most Western countries[11], and the
absence of previous investigations. Aim of the study was
the assessment of tissue expression of HSP72 and HSP27
in IHCCA resected with curative intention and the corre-
lation with patients survival.
Methods
Patients
Epidemiological data, from the Parma Tumor Registry
(Divisione di Oncologia Medica, Azienda Ospedaliera di
Parma), indicated a marked increase in the incidence of
IHCCA in our province from 1–2 cases/year to 9–12 cases/
year over the period 1994–2004. Base of the study was a
group of 31 patients with IHCCA who underwent resec-
tion with radical intent (R0) at the Dipartimento di Sci-
enze Chirurgiche, Sezione di Clinica Chirurgica Generale
e dei Trapianti d'Organo, over the period 1998–2006.
Background information including clinical-pathologic
data and patients' survival was retrieved from histological
and clinical records. None of the patients had received
chemotherapy or radiotherapy prior to surgery.
The study protocol was in accordance with the recommen-
dation of the Declaration of Helsinki. and the indications
of Italian DLgs no. 196/03 (Codex on Privacy). Written
consent to use stored tissue was obtained from all living
patients.
Sample sources
All pathological samples were retrieved from the archives
of the Dipartimento di Patologia e Medicina di Laborato-
rio – Sezione di Anatomia ed Istologia Patologica. Forma-
lin-fixed, paraffin-embedded, hematoxylin-eosin-stained
sections were reviewed and re-staged according to the
recent AJCC classification[12]. Representative areas of the
tumors, adjacent normal and dysplastic liver were selected
for immunohistochemistry studies.
Immunohistochemistry
Immunohistochemistry was performed as previously
described[13]. The paraffin sections were dewaxed, rehy-
drated, washed in Tris-buffered saline (TBS) (150 mmol/
L NaCl, 50 mmol/L Tris, pH 7.4). The antigen determi-
nants masked by formalin-fixation and paraffin-embed-
ding were exposed by heating the section in a microwave
oven for 10 min in an epitope retrieval solution (10 mM Tris
Base, 1 mM EDTA solution, 0.05% (v/v) Tween 20, pH
9.0). The endogenous peroxidase activity was quenched
with 3% H2O2 in deionized water for 10 min. Non-spe-
cific bindings were blocked in TBS containing 5% fraction
V bovine albumin (Sigma-Aldrich, St. Louis, MO, USA),
5% normal mouse serum (Dako Corp., Carpinteria, CA)
and 0.1% porcine gelatin type B (Sigma-Aldrich). Primary
monoclonal antibodies against HSP27, clone G3.1, and
inducible HSP72, clone C92F3A-5 (StressGene, Victoria,
BC Canada), and phosphorylated histone H3 (pHH3),
clone 8656-R (Santa Cruz Biotechnology, Inc. Santa Cruz,
CA), were used at 1:200, 1:600 and 1:50 dilutions, respec-
tively. All samples were incubated for 60 min with pri-
mary antibodies at room temperature.
Immunoperoxidase staining was performed using an anti-
Mouse/Rabbit Poly HRP Detection Kit (Chemicon Inter-
national, Temecula, CA) according to the manufacture's
specifications and developed with DAB. The specimens
were counterstained with hematoxylin, mounted and
examined by light microscopy. Routine negative controls
used TBS instead of the primary antibody. An isotype con-
trol was conducted using a mouse IgG isotype controlBMC Cancer 2007, 7:232 http://www.biomedcentral.com/1471-2407/7/232
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serum (Dako Corp., Carpinteria, CA). Negative and iso-
type controls were used in all staining runs. All negative
and isotype controls resulted in negative immunohisto-
chemical reactions.
The staining intensities of the IHCCAs were compared
with those of adjacent non-neoplastic biliary ducts by vis-
ual evaluation by three observers. Overexpression was
considered to be present when the intensity of tumor
staining was at least twice the staining intensity of adja-
cent non-neoplastic areas.
Mitotic count
Mitotic index of cancer cells was assessed by pHH3 stain-
ing, provide a simple and a reliable method for quantify-
ing proliferative potential and an indipendent predictor
of survival [14].
Image Analysis
The expression of HSP27 or HSP72 was evaluated using a
microscope image analysis system (Nikon Digital Net sys-
tem). For each patient, five randomized, non-overlapping
frames were evaluated in the same neoplastic area at 400×
field magnification (0.198 mm2·field). At least 50 posi-
tive cells were counted for a total of 250–500 cells ana-
lyzed. To assess reproducibility of the image analysis, the
pathologist blindly scored the 66% of the total of patients
and also randomly selected frames. Although agreement
was not exact in every case, no significant variation
between the investigators' analyses (PC, AAR, SD) was
noted.
Statistical analysis
The biomarker and clinical data were analyzed using S-
Plus Professional Edition v.6.1 (Insightful Corp., Seattle,
WA). Fisher's Exact Test was used to test the hypothesis of
independence between categorical variables in 2 × 2
tables. The ANOVA procedure was used to evaluate the
association between ordinal and categorical variables. All
tests were two-sided. The conversion of a continuous cov-
ariate into a binary one when there is no established cut-
off point (previous published results or biological knowl-
edge) was performed by using an outcome-oriented statis-
tical method (such as the optimal cutpoint estimation).
For optimal cutpoint estimation a corrected P value
method, as described by Hothorn and Lausen, was used.
Estimates of the survival probability were calculated using
the Kaplan-Meier method, and the log rank test was
employed to test the null hypothesis of equality in overall
survival among groups. The hazard ratio associated with
HSP27 and HSP72 expression was estimated by Cox haz-
ard-proportional regression.
Results
The study considered a eight year-period of inclusion,
with a satisfactory homogeneity of patients treated with
radical intent. The average age of the 20 females and 11
males undergoing surgery for IHCCA was 68 years (range
52–79). Two patients were positive to C viral hepatitis
(one of them showed B and C coinfection). None of the
other patients had underlying chronic liver disease. At
presentation, twelve patients had one comorbidity (dia-
betes, hypertension or heart disease), eight patients had
two comorbidities (mainly diabetes and hypertension),
and only two patients had three comorbidities (chronic
obstructive lung disease, diabetes and heart disease).
The surgical procedures, included: 8 right trisectionecto-
mies, 6 right and 4 left hemihepatectomies (including the
extended), 9 sectoriectomies (anterior, posterior and lat-
eral) and 4 segmentectomies. The mean liver volume
removed was 49 ± 19.2% (range 22–75%) while 4.6 ± 2.1
were the mean number of resected hepatic segments.
Twenty-four (77%) out of 31 tumors were well to moder-
ately differentiated, and 7 (23%) poorly differentiated.
The tumor growth pattern was papillary in eight cases,
glandular in ten, and solid in thirteen. Patient characteris-
tics are summarized in Table 1.
Table 1: Clinical-pathological features of patients affected by 
IHCCA who underwent surgery
Characteristics Total patients (N = 31)
Age at surgery 67.7 ± 7 yrs
Gender
Male 11
Female 20
Tumor greatest dimension#
<4 cm 8
4–6 cm 9
>6 cm 10
Histologic grade1#
Well/Moderate 20
Poor 8
Presence of tumor necrosis1#
<50% 9
>50% 22
Peritumoral border liver1#
Infiltrated 12
Pushed 18
Lymphoid infiltration1#
Absent 18
Present 10
Stage#
I6
II 5
III 17
1Estimated by pathologist; #data were not available for some patients.BMC Cancer 2007, 7:232 http://www.biomedcentral.com/1471-2407/7/232
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None of the 31 liver samples exhibited HSP27 or HSP72
expression in normal biliary tract epithelium, or in dys-
plastic areas. A low positivity was only observed in hepa-
tocytes lining tumor invasion border (not shown). This
low positivity could be related to the stress determined by
increasing mechanic pressure of the enlarging tumor mass
and similar to the stress response induced by high hydro-
static pressure in many types of mammalian cells[15].
Ten tumors samples (32%) were immunonegative for
HSPs, whereas 21 (68%) showed detectable immunoreac-
tivity for HSP27 or/and HSP72 (Figure 1). A single HSP27
or HSP72 immunopositivity was found in 6 and 7 sam-
ples, respectively, while in 8 samples concomitant expres-
sion of HSP27 and HSP72 was observed.
HSP27 expression was significantly associated with cell
proliferation as assessed by pHH3 staining (P-value =
0.0015) (Figure 2A), and was positively correlated with
main clinic-pathological features of tumor: its expression
showed a marginal significant (P-value = 0.047) correla-
tion to the greatest tumor dimension (4.36 ± 0.51 vs 6.05
± 0.57 cm) (Figure 2B). A significant correlation (P-value
= 0.004) between HSP27 and tumor vascular invasion was
also observed (Figure 2C). Both HSP27 expression (Figure
2D) and pHH3 count (Figure 3A) correlated with the Glis-
son's capsule invasion (P-value = 0.0122 and P-value =
0.0007, respectively).
pHH3 was associated with tumor greatest dimension and
vascular invasion (P-values of 0.0264 and 0.025, respec-
tively) (see Figure 3B and 3C). No significant correlation
between HSP27 and the remaining variables was observed
(Table 1). As to HSP72 expression, it was significantly
(Figure 4A) associated only with tumor necrosis (P-value
Immunoperoxidase staining Figure 1
Immunoperoxidase staining. Serial paraffin-embedded tissue sections of IHCCA show HSP27 and HSP72 expression in 
cholangiocarcinoma cells (brown staining). Left panels, 100× magnification; right panels, 200× magnification.BMC Cancer 2007, 7:232 http://www.biomedcentral.com/1471-2407/7/232
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= 0.010) and lymphoid infiltration (P-value = 0.0023)
(see Figure 4B).
Finally, we evaluated pHH3 and HSPs expression as pre-
dictors of survival. The percentage of pHH3 positive cells
was significantly lower in survivors than in patients died
for disease (2.71 ± 0.6% vs 4.98 ± 0.6%; P-value = 0.042).
Kaplan-Maier analysis showed that patients with pHH3
index above cutpoint (2.4%, P-value = 0.034) had a
shorter median overall survival (28.5 months) that did
the patients with pHH3 index below cutpoint (> 50
months) (P-value = 0.025). The aggregate expression of
HSPs was significantly associated (P-value = 0.0032) with
a marked decrease of overall survival rates: the median
survival for those patients with positivity for HSPs expres-
sion was 20.9 ± 8.3 months (with 13 deaths out of 21
patients) while was more than 57.5 months for those 10
patients without HSPs expression (only one patient died)
with a power of 0.73. We then evaluated the relative con-
tribution of the single expression of HSP27 or HSP72 to
patients' overall survival. The presence of HSP72 did not
affect patients'overall survival (53 vs 28.5 months P-value
= 0.155, with a power of 0.51). However, due to the low
value of power, we can not exclude that there is a statisti-
cally significant difference between the survival probabil-
ities of the 2 groups. As shown in Figure 5, the HSP27
expression (with the concomitant expression of HSP72)
was markedly associated (P-value = 0.0002) with a short
overall survival (median survival: 11 months, with 11
deaths out of 14 patients) while in the absence of HSP27
the median survival was above 55 months with 3 deaths
out of 17 patients. It is interesting to note that the pres-
HSP27 expression versus tumor parameters Figure 2
HSP27 expression versus tumor parameters. Box-and-whisker plots of HSP27 expression versus percentage of pHH3-
positive cells (A), and of HSP27 versus tumor greatest dimension (B). The open squares represent those outlier patients out-
side the 95% confidence interval. The black solid circles represent the mean values, while the line inside the box represents the 
median. Bar-chart plots of HSP27 expression versus frequency of vascular (C) and capsular (D) invasion.BMC Cancer 2007, 7:232 http://www.biomedcentral.com/1471-2407/7/232
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pHH3 cutpoint versus tumor progression parameters Figure 3
pHH3 cutpoint versus tumor progression parameters. Bar-chart plots of pHH3 below/above cutpoint versus frequency 
of vascular (A) and capsular (C) invasion. Box-and-whisker plots of pHH3 cutpoint versus tumor greatest dimension (B). The 
black solid circles represent the mean values, while the line inside the box represents the median.
HSP72 expression versus necrosis and lymphoid infiltration Figure 4
HSP72 expression versus necrosis and lymphoid infiltration. Bar-chart plots of HSP72 expression versus frequency of 
necrosis (A) and lymphoid infiltration (C).BMC Cancer 2007, 7:232 http://www.biomedcentral.com/1471-2407/7/232
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ence of HSP27, in the absence of HSP72, determined the
worst median survival (7 ± 3.2 months, with 4 deaths out
of 6 patients).
In our population, the following factors, when evaluated
by Cox regression univariate analysis (Table 2), signifi-
cantly predicted the risk of death: vascular invasion, Glis-
son's capsule invasion, HSP27 expression, and stage.
Owing to the stratification of the cohort, these last data
have to be regarded for exploratory purpose. Since our
cohort of patients was too small to detect independent
prognostic factors, multivariable regression analysis was
not performed.
Discussion
Surgical resection is the mainstay of curative treatment for
cholangiocarcinoma [1]. A neoadjuvant therapy or adju-
vant therapy with radiation or chemotherapy has not
been proven to prolong survival. Absence of lymph node
involvement, negative tumour margins up to 1 cm, soli-
tary lesions, and lack of microscopic vascular invasion
correlate with improved survival. The most important
prognostic factor after surgery is tumour-free surgical mar-
gins[3]. Even with careful selection and curative intent
(R0 surgery), the 5-year survival ratio ranges from 30% to
40%[3,16].
In the last few years considerable efforts have been
devoted to the search for markers of diagnosis and prog-
nosis of IHCCA [17-19]. For instance, we have shown [13]
that the combined expression of the Maspin and Bax pro-
teins appears to be a predictor of survival in IHCCA likely
influencing the susceptibility of tumor cholangiocytes to
apoptosis. Altough human cholangiocarcinoma do not
express the protooncogene Bcl-2, other antiapoptotic pro-
teins of the Bcl family such as Mcl-1 and Bcl-xl are
expressed[20]. Interestingly, Mcl-1 was found to mediate
TRAIL resistance in cholangiocarcinoma cells by blocking
the intrinsic pathway of apoptotic cell death[21]. In the
present study we show that the immunohistochemical
expression of HSP27 in tumor tissue significantly corre-
lates with patients survival and might be regarded as a
novel potential prognostic factor in IHCCA.
HSP27 and HSP72 are stress proteins inducible in
response to a wide variety of insults[22]. Being powerful
chaperones, their overexpression allows cells to survive
otherwise lethal conditions[6,23]. This cytoprotective
effect is related to their ability to disable apoptosis by act-
ing at multiple control points of the apoptotic path-
ways[7]. It has been suggested that HSP27 and HSP72
partecipate in oncogenesis since their overexpression and
Non parametric estimates of survival for HSP27 expression Figure 5
Non parametric estimates of survival for HSP27 
expression. This figure shows the estimated survival proba-
bilities based on the survival data of patients with presence 
or absence of HSP27 expression in their tumor samples.
Table 2: Cox univariate analysis
Variable Hazard Ratio 95%CI P-Value
Age 1.03 0.97 – 1.1 0.33
Gender 0.68 0.21 – 2.22 0.52
Tumor Border Growth(1) 3 0.85 – 10.6 0.088
Multiple nodules 0.923 0.31 – 2.75 0.89
Vascular Inv. 3.18 1.08 – 9.33 0.036
Capsular Inv. 3.95 1.20 – 12.9 0.024
Resected margins invasion 1.79 0.55 – 5.82 0.33
Tumor mass(2) 1.30 0.95 – 1.79 0.100
Number of resected segments 0.914 0.68 – 1.23 0.55
HSP27 18.5 3.83 – 89.6 0.0003
HSP72 1.99 0.66 – 5.94 0.22
Stage(3) 7.315 1.46 – 122.6 0.032
In bold are highlighted those variables with P-value < 0.05. (1)Microscopic tumor border growth; (2)Tumor greatest dimension; (3)Coded as Early 
Stage (Stage I-II) or Late Stage (Stage III-IV).BMC Cancer 2007, 7:232 http://www.biomedcentral.com/1471-2407/7/232
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the consequent inhibition of apoptosis can increase the
tumorigenic potential of cancer cells[6].
HSP27 interacts with key apoptosis-associated proteins
and inhibits cell death by a variety of mechanisms[24].
HSP27 can interfere with the intrinsic cell death pathway
by preventing the formation of the apoptosome[6], and
with the extrinsic apoptotic pathway by inhibiting Fas-
induced signaling[25]. Furthermore, HSP27 has been
shown to inhibit apoptosis by decreasing the reactive oxy-
gen species subsequently to increase of glutathione and
reduction of the toxic effect of oxidized proteins [26].
Recently, it has been characterized the tumorigenic role of
Fas/FasL in cholangiocarcinoma and it has been suggested
this pathway as a potential molecular target for therapeu-
tics strategies to circumvent apoptosis-resistance of
cholangiocarcinoma cells[27].
Higher than normal level of HSP27 expression was
detected in breast, prostate, bladder[28], gastric[29], ovar-
ian [30-32], and oral squamous carcinoma [33] cancers,
as well as in Hodgkin's disease[34]. HSP27 level is gener-
ally low or absent within unstressed cells and increases
during the stress response. However, the mechanisms that
regulate HSP27 mRNA and protein levels have yet to be
fully defined in cancer cells.
In our study the HSP27 expression in tumor tissue corre-
lated with poor clinical outcome. Independently of the
intensity of staining we also observed a significant associ-
ation of HSP27 expression to pathological parameters
related to tumor progression such as pHH3, gross tumor
greatest dimension, vascular and capsular inva-
sion[35,36]. It is interesting to note that this association
applied only to the expression of HSP27 and not of
HSP72. This observation is in agreement with recent
reports indicating that the knock-down of HSP27 with
siRNA or oligo anti-sense RNA in tumor cell lines induces
apoptosis and enhances sensitivity to chemotherapic
treatments[37,38]
Elevated expression of HSP72 either individually or in
combination with other HSPs (HSP27 or HSP90) has
been widely reported in several solid cancer[39], and var-
ious leukaemia [40-42]. The majority of the published
results indicate that HSP72 expression correlated with
poor prognosis and resistance to therapy. However, there
are contradictory data of HSP72 in some tumors: for
example, HSP72 expression correlated with poor progno-
sis in breast[43], endometrial[44,45], cervical/uterin can-
cer [39,46]. In contrast, high HSP72 expression correlated
with good prognosis in esophageal[47], pancreatic and
renal cancer[48]. Furthermore, HSP72 expression did not
correlate with prognosis in ovarian, oral head and neck,
oral squamous, gastric and prostate cancer.
Beside its antiapoptotic and tumorigenic role HSP72,
when released from cells undergoing necrosis, might exert
a proinflammatory effect owing to its interaction with
receptors on inflammatory cells[49]. Under massive
tumor necrosis the release of HSP72 can lead to specific
lymphocyte-mediated anti-tumor immune response[50]
that can induce tumor regression. Therefore, HSP72 can
exert both positive and negative effects on tumor growth.
Our results are in agreement with the aforementioned
proinflammatory effect of HSP72, supporting the role of
HSP72 in stimulating the immune response[51] and sug-
gest a duality of function (antiapoptotic vs proinflamma-
tory) in cancer development.
The present study suggests that HSP27 expression facili-
tates IHCCA progression likely by inhibiting apoptotic
cell death, and the assessment of HSP27 expression by
immunostaining in IHCCA might help to detect those
patients with a high risk of death. Accordingly, univariate
Cox regression analysis (see Table 2) shows a significant
relation between the presence of HSP27 and probability
to die.
The development of strategies targeting the modulation of
HSP27 expression in IHCCA may allow control over
tumor expansion and improve patients' survival. Down-
regulation of HSP27 gene expression by nucleotide-based
therapies or increased phosphorylation (inactivation) of
HSP27 protein by specific phosphatase inhibition could
also restore tumor cell sensitivity towards apoptosis and
chemosensitizes cells to chemotherapy [38].
Our study has the limitation of a low number of patients
that is too small to draw valid conclusions or conduct fur-
ther statistical analysis. However, our cohort represents a
large single institution series given the rarity of this tumor.
A multicentric and randomized trial will be required to
validate the results performed in this explorative retro-
spective study. If confirmed in a large independent trial,
the expression of HSP27 should help to discriminate
IHCCA patients with a better prognosis. Moreover, preop-
erative informations retrieved from liver needle biopsies
could provide a basis for selecting patients with a likely
favorable course for surgery enrolling.
Conclusion
Up to now there is no study of the relationship between
HSPs expression and patient's prognosis in IHCCA. In this
exploratory retrospective study the expression of HSP27
was found to be related to aggressive tumor behaviour.
The expression of HSP27 significantly worsened the
patients' median overall survival. The routinely histologi-
cal detection of HSP27 expression may provide a reliable
prognostic marker for IHCCA able to select those patients
with a likely favorable course for surgery enrolling.BMC Cancer 2007, 7:232 http://www.biomedcentral.com/1471-2407/7/232
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